PKI News and Press, PerkinElmer Inc. From 02/02/21

PerkinElmer (PKI): Q4 Non-GAAP EPS of $3.96 beats by $0.95; GAAP EPS of $3.38 beats by $0.75.Revenue of $1.36B (+68.8% Y/Y) beats by $140M.Press Release For further details see: PerkinElmer EPS beats by $0.95, beats on revenue

4Q Revenue of $1.355 billion; 68% reported growth; 65% organic growth 4Q GAAP EPS from continuing operations of $3.38; Adjusted EPS of $3.96 Initiates First Quarter and Full Year 2021 Guidance PerkinElmer, Inc . (NYSE: PKI), a global leader committed ...

Looking For The Top Biotech Stocks To Buy In February? Any investors worth their salt can tell you that biotech stocks are among the top performers on the stock market today . Whether it is explosive gains within a day or long-term gains, the industry has benefitted investor...

[[ALGM]], [[AMCR]], [[AMGN]], [[AMZN]], [[APAM]], [[ATGE]], [[ATO]], [[BDN]], [[BRKS]], [[CB]], [[CMG]], [[DOX]], [[EA]], [[EPAY]], [[FBHS]], [[FEYE]], [[GL]], [[GOOG]], [[ICHR]], [[MANH]], [[MRCY]], [[MTCH]], [[PKI]], [[POWI]], [[SANM]], [[STE]], [[TENB]], [[VIAV]]For Seeking Alpha's full ea...

PerkinElmer (NYSE:PKI) is scheduled to announce Q4 earnings results on Tuesday, February 2nd, after market close.The consensus EPS Estimate is $3.01 and the consensus Revenue Estimate is $1.22B (+51.5% Y/Y).Over the last 2 years, PKI has beaten EPS estimates 88% of the time and has beate...

Growth stocks have been outperforming their value counterparts since last year. And because coronavirus-pandemic-driven trends are expected to continue this year, Skyworks Solutions, Inc. (SWKS), PerkinElmer, Inc. (PKI), Chegg, Inc. (CHGG), and Wingstop, Inc. (WING) are positioned nicely to w...

Oxford Immunotec will be acquired by PerkinElmer in an all-cash deal for $22/share. The offer represents a c. 28% premium to the previous closing price at time of announcement and implies a c. 5x revenue multiple. This will likely be a solid bolt-on for PerkinElmer considering the...

PerkinElmer is absolutely on fire as preliminary fourth quarter results reveal. PerkinElmer is not a one-trick pony. It has been a long-term value creator for investors. I still like the long-term potential of the company and shares, yet here and now momentum seems a bit too stron...

PerkinElmer ([[PKI]] +0.3%) said its New Coronavirus Nucleic Acid Detection Kit received Emergency Use Authorization ((EUA)) from the FDA to test individuals without symptoms or other reasons to suspect COVID-19 infection.Previously, the FDA issued EUA to allow sample pooling w...

Gold-standard testing of individuals without COVID-19 symptoms key to controlling the spread PerkinElmer, Inc. (NYSE:PKI) announced today that its PerkinElmer ® New Coronavirus Nucleic Acid Detection Kit received Emergency Use Authorization (EUA) from the U....